Please enable JavaScript to continue using this application.

Compare $ACAD vs $VKTX | Chartloom

Compare

$ACAD vs $VKTX

ACADIA Pharmaceuticals Inc · Viking Therapeutics Inc

ACAD

ACADIA Pharmaceuticals Inc

VKTX

Viking Therapeutics Inc

Compare $ACAD vs $VKTX

Comparing ACADIA Pharmaceuticals Inc and Viking Therapeutics Inc

ACADACADIA Pharmaceuticals Inc

VKTXViking Therapeutics Inc

ACADACADIA Pharmaceuticals Inc

Market cap

$3.39B

P/E (TTM)

8.99x

Forward P/E (NTM)

23.42x

Forward P/S (NTM)

2.37x

Rev growth (TTM)

48.3%

YTD performance

-24.8%

52W performance

-7.2%

FCF yield

4.3%

VKTXViking Therapeutics Inc

Market cap

$3.33B

P/E (TTM)

—

Forward P/E (NTM)

—

Forward P/S (NTM)

—

Rev growth (TTM)

—

YTD performance

-19.5%

52W performance

-11.9%

FCF yield

-12.6%

Add ticker

Add up to 1 more ticker to compare

Relative performance

Each ticker starts at 100. 110 means +10% from the start of this window — not a $110 share price.

ACAD

VKTX

Detailed metrics comparison

ACAD

ACADIA Pharmaceuticals Inc

VKTX

Viking Therapeutics Inc

Market Cap

ACAD$3.39B

VKTX$3.33B

Enterprise Value

ACAD$3.00B

VKTX$3.20B

Price

ACAD$19.78

VKTX$28.51

P/E Ratio

ACAD8.99x

VKTXN/A

P/S Ratio

ACAD2.97x

VKTX0.00x

EV/Sales

ACAD2.64x

VKTX0.00x

EV/EBITDA

ACAD24.70x

VKTX0.00x

P/B Ratio

ACAD2.63x

VKTX9.38x

P/FCF Ratio

ACAD23.26x

VKTXN/A

EV/FCF

ACAD20.62x

VKTX-7.65x

PEG Ratio

ACAD0.13x

VKTXN/A

Forward P/E (NTM)

ACAD23.42x

VKTXN/A

Forward P/S (NTM)

ACAD2.37x

VKTXN/A

Revenue (TTM)

ACAD$1.14B

VKTX$0

Revenue Growth (YoY)

ACAD48.3%

VKTXN/A

Forward Rev Growth

ACAD12.6%

VKTX236.5%

Gross Margin (TTM)

ACAD91.1%

VKTX0.0%

Operating Margin (TTM)

ACAD7.6%

VKTX0.0%

EBITDA Margin (TTM)

ACAD8.6%

VKTX0.0%

Net Margin (TTM)

ACAD33.4%

VKTX0.0%

FCF Margin (TTM)

ACAD12.8%

VKTXN/A

Net Income (TTM)

ACAD$380M

VKTX$-535M

FCF (TTM)

ACAD$146M

VKTX$-418M

EPS (TTM)

ACAD$2.20

VKTX-$4.60

ROE (TTM)

ACAD32.4%

VKTX-9456.0%

ROA (TTM)

ACAD24.4%

VKTX-8274.0%

ROIC (TTM)

ACAD32.4%

VKTX-9456.0%

Cash

ACAD$385M

VKTX$126M

Debt

ACAD$0

VKTX$0

Net Cash/Debt

ACAD$385M

VKTX$126M

Current Ratio (TTM)

ACAD3.39x

VKTX4.72x

Quick Ratio (TTM)

ACAD3.11x

VKTX4.57x

Debt/Equity (TTM)

ACAD0.00x

VKTX0.00x

Debt/Assets (TTM)

ACAD0.0%

VKTX0.0%

Interest Coverage (TTM)

ACADN/A

VKTXN/A

Net Debt/EBITDA (TTM)

ACAD0.00x

VKTX0.00x

Beta

ACAD0.91

VKTX0.69

52W Performance

ACAD-7.2%

VKTX-11.9%

YTD Performance

ACAD-24.8%

VKTX-19.5%

% from 52W High

ACAD-36.1%

VKTX-33.9%

% from 52W Low

ACAD2.4%

VKTX10.6%

Asset Turnover (TTM)

ACAD0.73x

VKTX0.00x

FCF Yield (TTM)

ACAD4.3%

VKTX-12.6%

Earnings Yield (TTM)

ACAD11.2%

VKTX-16.1%

Dividend Yield (TTM)

ACADN/A

VKTXN/A

Rule of 40

ACAD61.1

VKTX0.0

EV/GP/RG

ACAD0.09

VKTXN/A

Ticker research

View ACAD research View VKTX research

Metric	ACAD ACADIA Pharmaceuticals Inc	VKTX Viking Therapeutics Inc
Market & Valuation
Market Cap	$3.39B	$3.33B
Enterprise Value	$3.00B	$3.20B
Price	$19.78	$28.51
P/E Ratio	8.99x	N/A
P/S Ratio	2.97x	0.00x
EV/Sales	2.64x	0.00x
EV/EBITDA	24.70x	0.00x
P/B Ratio	2.63x	9.38x
P/FCF Ratio	23.26x	N/A
EV/FCF	20.62x	-7.65x
PEG Ratio	0.13x	N/A
Forward P/E (NTM)	23.42x	N/A
Forward P/S (NTM)	2.37x	N/A
Revenue & Growth
Revenue (TTM)	$1.14B	$0
Revenue Growth (YoY)	48.3%	N/A
Forward Rev Growth	12.6%	236.5%
Profitability
Gross Margin (TTM)	91.1%	0.0%
Operating Margin (TTM)	7.6%	0.0%
EBITDA Margin (TTM)	8.6%	0.0%
Net Margin (TTM)	33.4%	0.0%
FCF Margin (TTM)	12.8%	N/A
Net Income (TTM)	$380M	$-535M
FCF (TTM)	$146M	$-418M
EPS (TTM)	$2.20	-$4.60
ROE (TTM)	32.4%	-9456.0%
ROA (TTM)	24.4%	-8274.0%
ROIC (TTM)	32.4%	-9456.0%
Financial Health
Cash	$385M	$126M
Debt	$0	$0
Net Cash/Debt	$385M	$126M
Current Ratio (TTM)	3.39x	4.72x
Quick Ratio (TTM)	3.11x	4.57x
Debt/Equity (TTM)	0.00x	0.00x
Debt/Assets (TTM)	0.0%	0.0%
Interest Coverage (TTM)	N/A	N/A
Net Debt/EBITDA (TTM)	0.00x	0.00x
Performance
Beta	0.91	0.69
52W Performance	-7.2%	-11.9%
YTD Performance	-24.8%	-19.5%
% from 52W High	-36.1%	-33.9%
% from 52W Low	2.4%	10.6%
Efficiency & Yields
Asset Turnover (TTM)	0.73x	0.00x
FCF Yield (TTM)	4.3%	-12.6%
Earnings Yield (TTM)	11.2%	-16.1%
Dividend Yield (TTM)	N/A	N/A
Other
Rule of 40	61.1	0.0
EV/GP/RG	0.09	N/A
Ticker research	View ACAD research	View VKTX research

Valuation

P/E Ratio

ACAD

8.99x

P/S Ratio

VKTX

0.00x

ACAD

2.97x

EV/FCF

VKTX

-7.65x

ACAD

20.62x

Growth & revenue

Revenue Growth TTM

ACAD

48.3%

Forward Revenue Growth

VKTX

236.5%

ACAD

12.6%

Profitability & performance

Gross Margin

ACAD

91.1%

VKTX

0.0%

ROE

ACAD

32.4%

VKTX

-9456.0%

FCF Yield %

ACAD

4.3%

VKTX

-12.6%

52-Week Performance

ACAD

-7.2%

VKTX

-11.9%

Detailed metrics comparison

ACAD

ACADIA Pharmaceuticals Inc

VKTX

Viking Therapeutics Inc

Market Cap

ACAD$3.39B

VKTX$3.33B

Enterprise Value

ACAD$3.00B

VKTX$3.20B

Price

ACAD$19.78

VKTX$28.51

P/E Ratio

ACAD8.99x

VKTXN/A

P/S Ratio

ACAD2.97x

VKTX0.00x

EV/Sales

ACAD2.64x

VKTX0.00x

EV/EBITDA

ACAD24.70x

VKTX0.00x

P/B Ratio

ACAD2.63x

VKTX9.38x

P/FCF Ratio

ACAD23.26x

VKTXN/A

EV/FCF

ACAD20.62x

VKTX-7.65x

PEG Ratio

ACAD0.13x

VKTXN/A

Forward P/E (NTM)

ACAD23.42x

VKTXN/A

Forward P/S (NTM)

ACAD2.37x

VKTXN/A

Revenue (TTM)

ACAD$1.14B

VKTX$0

Revenue Growth (YoY)

ACAD48.3%

VKTXN/A

Forward Rev Growth

ACAD12.6%

VKTX236.5%

Gross Margin (TTM)

ACAD91.1%

VKTX0.0%

Operating Margin (TTM)

ACAD7.6%

VKTX0.0%

EBITDA Margin (TTM)

ACAD8.6%

VKTX0.0%

Net Margin (TTM)

ACAD33.4%

VKTX0.0%

FCF Margin (TTM)

ACAD12.8%

VKTXN/A

Net Income (TTM)

ACAD$380M

VKTX$-535M

FCF (TTM)

ACAD$146M

VKTX$-418M

EPS (TTM)

ACAD$2.20

VKTX-$4.60

ROE (TTM)

ACAD32.4%

VKTX-9456.0%

ROA (TTM)

ACAD24.4%

VKTX-8274.0%

ROIC (TTM)

ACAD32.4%

VKTX-9456.0%

Cash

ACAD$385M

VKTX$126M

Debt

ACAD$0

VKTX$0

Net Cash/Debt

ACAD$385M

VKTX$126M

Current Ratio (TTM)

ACAD3.39x

VKTX4.72x

Quick Ratio (TTM)

ACAD3.11x

VKTX4.57x

Debt/Equity (TTM)

ACAD0.00x

VKTX0.00x

Debt/Assets (TTM)

ACAD0.0%

VKTX0.0%

Interest Coverage (TTM)

ACADN/A

VKTXN/A

Net Debt/EBITDA (TTM)

ACAD0.00x

VKTX0.00x

Beta

ACAD0.91

VKTX0.69

52W Performance

ACAD-7.2%

VKTX-11.9%

YTD Performance

ACAD-24.8%

VKTX-19.5%

% from 52W High

ACAD-36.1%

VKTX-33.9%

% from 52W Low

ACAD2.4%

VKTX10.6%

Asset Turnover (TTM)

ACAD0.73x

VKTX0.00x

FCF Yield (TTM)

ACAD4.3%

VKTX-12.6%

Earnings Yield (TTM)

ACAD11.2%

VKTX-16.1%

Dividend Yield (TTM)

ACADN/A

VKTXN/A

Rule of 40

ACAD61.1

VKTX0.0

EV/GP/RG

ACAD0.09

VKTXN/A

Ticker research

View ACAD research View VKTX research

Metric	ACAD ACADIA Pharmaceuticals Inc	VKTX Viking Therapeutics Inc
Market & Valuation
Market Cap	$3.39B	$3.33B
Enterprise Value	$3.00B	$3.20B
Price	$19.78	$28.51
P/E Ratio	8.99x	N/A
P/S Ratio	2.97x	0.00x
EV/Sales	2.64x	0.00x
EV/EBITDA	24.70x	0.00x
P/B Ratio	2.63x	9.38x
P/FCF Ratio	23.26x	N/A
EV/FCF	20.62x	-7.65x
PEG Ratio	0.13x	N/A
Forward P/E (NTM)	23.42x	N/A
Forward P/S (NTM)	2.37x	N/A
Revenue & Growth
Revenue (TTM)	$1.14B	$0
Revenue Growth (YoY)	48.3%	N/A
Forward Rev Growth	12.6%	236.5%
Profitability
Gross Margin (TTM)	91.1%	0.0%
Operating Margin (TTM)	7.6%	0.0%
EBITDA Margin (TTM)	8.6%	0.0%
Net Margin (TTM)	33.4%	0.0%
FCF Margin (TTM)	12.8%	N/A
Net Income (TTM)	$380M	$-535M
FCF (TTM)	$146M	$-418M
EPS (TTM)	$2.20	-$4.60
ROE (TTM)	32.4%	-9456.0%
ROA (TTM)	24.4%	-8274.0%
ROIC (TTM)	32.4%	-9456.0%
Financial Health
Cash	$385M	$126M
Debt	$0	$0
Net Cash/Debt	$385M	$126M
Current Ratio (TTM)	3.39x	4.72x
Quick Ratio (TTM)	3.11x	4.57x
Debt/Equity (TTM)	0.00x	0.00x
Debt/Assets (TTM)	0.0%	0.0%
Interest Coverage (TTM)	N/A	N/A
Net Debt/EBITDA (TTM)	0.00x	0.00x
Performance
Beta	0.91	0.69
52W Performance	-7.2%	-11.9%
YTD Performance	-24.8%	-19.5%
% from 52W High	-36.1%	-33.9%
% from 52W Low	2.4%	10.6%
Efficiency & Yields
Asset Turnover (TTM)	0.73x	0.00x
FCF Yield (TTM)	4.3%	-12.6%
Earnings Yield (TTM)	11.2%	-16.1%
Dividend Yield (TTM)	N/A	N/A
Other
Rule of 40	61.1	0.0
EV/GP/RG	0.09	N/A
Ticker research	View ACAD research	View VKTX research